Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares Purchased by Investment House LLC

Investment House LLC grew its position in shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 9.9% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 945 shares of the pharmaceutical company’s stock after acquiring an additional 85 shares during the quarter. Investment House LLC’s holdings in Vertex Pharmaceuticals were worth $381,000 at the end of the most recent quarter.

A number of other large investors also recently modified their holdings of the company. Dunhill Financial LLC lifted its holdings in shares of Vertex Pharmaceuticals by 70.6% during the 3rd quarter. Dunhill Financial LLC now owns 58 shares of the pharmaceutical company’s stock valued at $27,000 after acquiring an additional 24 shares in the last quarter. Brown Lisle Cummings Inc. acquired a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth about $30,000. Legacy Investment Solutions LLC acquired a new stake in shares of Vertex Pharmaceuticals in the third quarter valued at about $33,000. Truvestments Capital LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 3rd quarter valued at about $35,000. Finally, Sugar Maple Asset Management LLC purchased a new stake in shares of Vertex Pharmaceuticals during the 4th quarter valued at about $35,000. 90.96% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several brokerages have issued reports on VRTX. HC Wainwright reaffirmed a “buy” rating and issued a $550.00 price objective on shares of Vertex Pharmaceuticals in a research report on Tuesday, February 11th. StockNews.com raised shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Tuesday, March 11th. Royal Bank of Canada boosted their price objective on shares of Vertex Pharmaceuticals from $407.00 to $408.00 and gave the stock a “sector perform” rating in a report on Thursday, February 20th. Oppenheimer downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Thursday, December 19th. Finally, Canaccord Genuity Group upgraded Vertex Pharmaceuticals from a “sell” rating to a “hold” rating and boosted their price target for the stock from $408.00 to $424.00 in a research note on Tuesday, February 11th. Ten analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Vertex Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $506.70.

Insider Activity

In related news, EVP David Altshuler sold 3,231 shares of Vertex Pharmaceuticals stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $500.00, for a total transaction of $1,615,500.00. Following the sale, the executive vice president now directly owns 26,512 shares in the company, valued at $13,256,000. The trade was a 10.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Ourania Tatsis sold 244 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $455.06, for a total transaction of $111,034.64. Following the completion of the transaction, the executive vice president now owns 67,695 shares of the company’s stock, valued at $30,805,286.70. This represents a 0.36 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,315 shares of company stock valued at $2,121,012. Insiders own 0.20% of the company’s stock.

Vertex Pharmaceuticals Price Performance

Shares of NASDAQ VRTX opened at $512.52 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.69 and a quick ratio of 2.35. The firm has a market capitalization of $131.61 billion, a PE ratio of -232.96, a P/E/G ratio of 2.11 and a beta of 0.41. Vertex Pharmaceuticals Incorporated has a 1-year low of $377.85 and a 1-year high of $519.88. The business’s fifty day moving average price is $464.06 and its two-hundred day moving average price is $462.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings data on Monday, February 10th. The pharmaceutical company reported $3.54 earnings per share for the quarter, missing the consensus estimate of $3.99 by ($0.45). Vertex Pharmaceuticals had a negative net margin of 4.86% and a negative return on equity of 2.02%. On average, research analysts expect that Vertex Pharmaceuticals Incorporated will post 15.63 EPS for the current year.

Vertex Pharmaceuticals Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.